医学
肝细胞癌
肝硬化
内科学
脂肪肝
胃肠病学
人口
疾病
环境卫生
作者
Simone Conci,Federica Cipriani,Matteo Donadon,Ivan Marchitelli,Francesco Ardito,Simone Famularo,Pasquale Perri,Maurizio Iaria,Luca Ansaloni,Matteo Zanello,Giuliano La Barba,Stefan Patauner,Enrico Pinotti,Sarah Molfino,Paola Germani,Maurizio Romano,Ivano Sciannamea,Cecilia Ferrari,Alberto Manzoni,Albert Troci
出处
期刊:Ejso
[Elsevier BV]
日期:2021-07-24
卷期号:48 (1): 103-112
被引量:28
标识
DOI:10.1016/j.ejso.2021.07.015
摘要
We investigated the clinical impact of the newly defined metabolic-associated fatty liver disease (MAFLD) in patients undergoing hepatectomy for HCC (MAFLD-HCC) comparing the characteristics and outcomes of patients with MAFLD-HCC to viral- and alcoholic-related HCC (HCV-HCC, HBV-HCC, A-HCC).A retrospective analysis of patients included in the He.RC.O.Le.S. Group registry was performed. The characteristics, short- and long-term outcomes of 1315 patients included were compared according to the study group before and after an exact propensity score match (PSM).Among the whole study population, 264 (20.1%) had MAFLD-HCC, 205 (15.6%) had HBV-HCC, 671 (51.0%) had HCV-HCC and 175 (13.3%) had A-HCC. MAFLD-HCC patients had higher BMI (p < 0.001), Charlson Comorbidities Index (p < 0.001), size of tumour (p < 0.001), and presence of cirrhosis (p < 0.001). After PSM, the 90-day mortality and severe morbidity rates were 5.9% and 7.1% in MAFLD-HCC, 2.3% and 7.1% in HBV-HCC, 3.5% and 11.7% in HCV-HCC, and 1.2% and 8.2% in A-HCC (p = 0.061 and p = 0.447, respectively). The 5-year OS and RFS rates were 54.4% and 37.1% in MAFLD-HCC, 64.9% and 32.2% in HBV-HCC, 53.4% and 24.7% in HCV-HCC and 62.0% and 37.8% in A-HCC (p = 0.345 and p = 0.389, respectively). Cirrhosis, multiple tumours, size and satellitosis seems to be the independent predictors of OS.Hepatectomy for MAFLD-HCC seems to have a higher but acceptable operative risk. However, long-term outcomes seems to be related to clinical and pathological factors rather than aetiological risk factors.
科研通智能强力驱动
Strongly Powered by AbleSci AI